Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature
Cytokine release syndrome (CRS) can be induced by immune checkpoint inhibitors (ICIs). Although the incidence of CRS is low, it is often underreported. Here, we report two severe CRS cases and summarize and review 51 patients with ICI-induced CRS to explore the possible contributing factors to the d...
Main Authors: | Yujing Zhang, Xiaoyue Wen, Yaqi OuYang, Yingying Hu, Xiangzhi Fang, Jiancheng Zhang, Yin Yuan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024004110 |
Similar Items
-
Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature
by: Sen Hee Tay, et al.
Published: (2022-01-01) -
Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non‐small cell lung cancer: A case report
by: Toshiharu Tsutsui, et al.
Published: (2023-08-01) -
A case of cytokine release syndrome accompanied with COVID‐19 infection during treatment with immune checkpoint inhibitors for non‐small cell lung cancer
by: Daiki Murata, et al.
Published: (2022-10-01) -
Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01) -
Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)